Journal Information
Vol. 42. Issue 1.
Pages 98-99 (January - March 2020)
Share
Share
Download PDF
More article options
Visits
...
Vol. 42. Issue 1.
Pages 98-99 (January - March 2020)
Letter to the Editor
DOI: 10.1016/j.htct.2019.01.008
Open Access
Intravenous ferric carboxymaltose for the treatment of iron deficiency anemia: Letter to Editor
Visits
...
Sakiyeva Kanshaiyma, Gulmira Zhurabekovaa, Ibrahim A. Abdelazimb,c,
Corresponding author
dr.ibrahimanwar@gmail.com

Corresponding author at: Ahmadi Kuwait Oil (KOC), Company Hospital, Ahmadi, Kuwait.
, Tatyana Starchenkoa
a Marat Ospanov, West Kazakhstan State Medical University (WKSMU), Aktobe, Kazakhstan
b Ain Shams University, Cairo, Egypt
c Ahmadi Hospital, Kuwait Oil Company, Ahmadi, Kuwait
Article information
Full Text
Bibliography
Download PDF
Statistics
Full Text
Dear Respectable Editor,

While we are reading with great interest the article published by Friedrisch et al. in the Revista Brasileira de Hematologia e Hemoterapia 2015;37(6):400–5. doi:10.1016/j.bjhh.2015.08.012, many questions came to mind. We would be grateful if the authors clarified the following queries to us and to the readers.

First, Friedrisch et al., stated that treatment with intravenous ferric carboxymaltose (FCM) improves indices of anemia, hemoglobin, ferritin and trans-ferrin saturation values.1

Other authors mentioned that the efficacy of the parenteral iron infusion used for treatment of iron deficiency anemia (IDA), checked by comparing the pre-treatment hemoglobin concentration, serum ferritin, mean corpuscular volume and mean corpuscular hemoglobin with the post-treatment value.2–6

Second, Friedrisch et al. stated that the intravenous FCM properties permit the administration of large doses (15mg/kg, maximum of 1000mg/infusion) in a single and rapid session (15-min infusion), without the requirement of a test dose.1

Other authors stated that the total parenteral dose for correction of IDA should be given and calculated according to the body weight, hemoglobin deficiency and depleted iron stores, using the following formula: total parenteral iron needed in mg=2.4×pre-pregnancy weight in kg×(target hemoglobinactual hemoglobin)g/dL+500mg. Twelve (12) g/dL is the target hemoglobin concentration, 2.4 is the correction factor and 500mg is the amount of stored iron in pregnant adult women.2–8

Recently, Froessler et al. applied another regimen of 20mg/kg body-weight of FCM for treatment of IDA in pregnancy with a maximum dose of 1000mg in a single infusion and they stated that an ideal dosing regimen currently does not exist.9,10

Please clarify to us and to the readers the ideal method for checking the efficacy of parenteral iron treatment and the ideal method for the calculation of the total parenteral iron needed for treatment of IDA in pregnancy.

Conclusion

The efficacy of the parenteral iron infusion used for treatment of IDA is checked by comparing the pre-treatment hemoglobin concentration, serum ferritin, MCV and MCH with the post-treatment value. Total parenteral dose for correction of IDA should be given and calculated according to the body weight, hemoglobin deficiency and depleted iron stores, using the following formula: total iron needed in mg=2.4×pre-pregnancy weight in kg×(target hemoglobinactual hemoglobin) g/dL+500mg. Twelve (12) g/dL is the target hemoglobin concentration, 2.4 is the correction factor and 500mg is the amount of stored iron in pregnant adult women.

Compliance with ethics guidelines.

Authors’ contributions

SK is responsible for the idea for the letter, intellectual content and update of references. GZ is responsible for the Microsoft editing and update of references. IAA is responsible for the design and submission for publication. TS is responsible for the intellectual content and update of references.

Ethical approval

This article does not contain any studies with human or animal subjects performed by any of the authors.

Conflicts of interest

The authors declare no conflicts of interest.

References
[1]
J.R. Friedrisch, R.D. Cançado.
Intravenous ferric carboxymaltose for the treatment of iron deficiency anemia.
Rev Bras Hematol Hemoter, 37 (2015), pp. 400-405
[2]
I.A. Abdelazim, B. Nusair, S. Svetlana, G. Zhurabekova.
Treatment of iron deficiency and iron deficiency anemia with intravenous ferric carboxymaltose in pregnancy.
Arch Gynecol Obstet, 298 (2018), pp. 1231-1232
[3]
I.A. Abdelazim, M. Abu-Faza, A.A. Elbiaa, H.S. Othman, D.A. Alsharif, W.F. Elsawah.
Heme iron polypeptide (proferrin®-ES) versus iron saccharate complex (ferrosac) for treatment of iron deficiency anemia during pregnancy.
Acta Med Int, 4 (2017), pp. 56-61
[4]
D. Shafi, S.V. Purandare, A.V. Sathe.
Iron deficiency anemia in pregnancy: intravenous versus oral route.
J Obstet Gynaecol India, 62 (2012), pp. 317-321
[5]
F. Bayoumeu, C. Subiran-Buisset, N.E. Baka, H. Legagneur, P. Monnier-Barbarino, M.C. Laxenaire.
Iron therapy in iron deficiency anemia in pregnancy: intravenous route versus oral route.
Am J Obstet Gynecol, 186 (2002), pp. 518-522
[6]
S.B. Bhavi, P.B. Jaju.
Intravenous iron sucrose v/s oral ferrous fumarate for treatment of anemia in pregnancy. A randomized controlled trial.
BMC Pregnancy Childbirth, 17 (2017), pp. 137
[7]
A. Barut, M. Harma.
Intravenous iron treatment for iron deficiency anemia in pregnancy.
J Turkish-German Gynecol Assoc, 10 (2009), pp. 109-115
[8]
K. Kalaivani.
Prevalence and consequences of anemia in pregnancy.
Indian J Med Res, 130 (2009), pp. 627-633
[9]
B. Froessler, T. Gajic, G. Dekker, N.A. Hodyl.
Treatment of iron deficiency and iron deficiency anemia with intravenous ferric carboxymaltose in pregnancy.
Arch Gynecol Obstet, 298 (2018), pp. 75-82
[10]
B. Froessler, T. Gajic, G. Dekker, N.A. Hodyl.
Response to letter to the Editor: Treatment of iron deficiency and iron deficiency anemia with intravenous ferric carboxymaltose in pregnancy.
Arch Gynecol Obstet, 298 (2018), pp. 1233-1234
Copyright © 2019. Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular
Idiomas
Hematology, Transfusion and Cell Therapy

Subscribe to our newsletter

Article options
Tools
en pt
Cookies policy Política de cookies
To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.